Sunderland Joint Formulary
NHS Sunderland Clinical Commissioning Group
South Tyneside and Sunderland NHS Foundation Trust

 
back
11 Eye
11-08-02 Subfoveal choroidal neovascularisation

*Avastin is available as a treatment option for wet AMD in situations where ophthalmologists feel, in discussion with their patients, that the licensed options are unsuitable. See chapter 8 for product details.


Aflibercept
Formulary

Intravitreal injection: 4 mg/ 0.1mL (dose 2mg/0.05ml)

Link  NICE TA 409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Link  NICE TA 486: Aflibercept for treating choroidal neovascularisation
Link  NICE TA294: Macular degeneration (wet age-related) - aflibercept
Link  NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Link  NICE TA346: Aflibercept for treating diabetic macular oedema
 

Red View adult BNF  View SPC online  HCD
Brolucuzumab
Formulary

Intravitreal injection: 120mg/1mL (dose 6mg/0.05ml)

Link  NICE TA 672: Brolucizumab for treating wet age-related macular degeneration
 

Red View adult BNF  View SPC online  HCD
Ranibizumab
Formulary

Intravitreal injection: 10mg in 1ml as a 0.23ml vial (dose 0.5mg/0.05ml)

Link  NICE TA274: Macular oedema (diabetic) - ranibizumab
Link  NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance
Link  NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab
 

Red View adult BNF  View SPC online  HCD
Verteporfin
Formulary

Injection: 15 mg


Red View adult BNF  View SPC online  HCD
Pegaptanib Sodium Macugen®
Non Formulary
Link  NICE TA155: guidance on pegaptanib in AMD (August 2008)
 

View adult BNF  View SPC online  HCD